Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: longnshort who wrote (330887)	3/31/2007 12:38:04 PM
From: tejek	Read Replies (1) \| Respond to of 1577095

Ted you posted that you didn't like STKR because you NEVER buy stocks that don't have earning. DNDN had a lost of 1.27 per share last year. I think you are truth impaired. You're right. I typically don't buy speculative stocks. I made an exception with DNDN for a number of reasons: its a local biotech and its principals have very good reputations, a number of local heavyweights own a lot of the stock, and my cousin says that their cancer drug, Provenge, is the wave of the future. So I took a chance and its paying off nicely. I am expecting the stock to pull back before their May 15th meeting in front of the FDA. You might want to pick up some. Analysts were saying before the FDA panel meeting on Thursday that Provenge is likely to be a billion dollar drug and DNDN's stock could well go up to $27.